MedPath

Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy

Phase 1
Conditions
Duchenne Muscular Dystrophy
Interventions
Biological: Umbilical Cord Mesenchymal Stem Cell
Registration Number
NCT02285673
Lead Sponsor
Acibadem University
Brief Summary

Duchenne muscular dystrophy (DMD) is a genetic disorder caused by an absence of dystrophin and characterized by progressive muscle degeneration. There is no cure for DMD at present but, there are several strategies under-researched for treatment of DMD such as steroid treatment, gene theraphy, exon skipping, stop codon read through and gene repair, cell theraphy and theraphy with drug that help to produce utrophin protein.

The aim of this study is investigate the eficacy of human umblical cord mesenchymal stem cells on DMD and understanding if wild type gene can be transfered to the patient.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
10
Inclusion Criteria
  • Patients with diagnosis of DMD that is proven clinically and genetically Age between 7-20 Patients need partial respiratory support, during the day Patients have less than or equal to stage I NIH, Liver, renal and cardiac function Patients without cancer Patients without allergic disease Patients without bleeding diathesis,
Exclusion Criteria

Patients need complete respiratory support Patients have more than to stage II NIH, Liver, renal and cardiac function Patients have bleeding diathesis and allergic disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Umbilical Cord Mesenchymal Stem CellUmbilical Cord Mesenchymal Stem Cell-
Primary Outcome Measures
NameTimeMethod
Duchenne muscular dystrophy gene expressionup to 9 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Acibadem Labcell

🇹🇷

Istanbul, Uskudar, Turkey

© Copyright 2025. All Rights Reserved by MedPath